Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Syros Pharmaceuticals Inc
SYRS | US
2.24
USD0.28
14.29%
SYRS | US
About Syros Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.24
Open
1.93
High
2.24
Low
1.89
Syros Pharmaceuticals Inc. a biopharmaceutical company focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene a selective retinoic acid receptor alpha agonist which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101 a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609 a cyclin-dependent kinase 7 inhibitor which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery research collaboration and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22 Inc. and changed its name to Syros Pharmaceuticals Inc. in August 2012. Syros Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Cambridge Massachusetts.
View LessSYRS | US
Risk
78.0
Sharpe
-0.05
Luna's Score
43/100
Recommendation
Sell
Luna says (SYRS | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
75.6%1 month
78.0%3 months
151.0%6 months
115.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
10.65
Debt to equity
-9.55
Debt to assets
0.57
Ent. to EBITDA
-0.41
Ent. to rev.
8.25
PEG
-
Other Fundamentals
EBITDA
-116.00M
MarketCap
60.05M
MarketCap(USD)
60.05M
Div. yield
-
Op. margin
-2.83K
Erngs. growth
-
Rev. growth
-3.30
Ret. on equity
-393.39
Short ratio
3.01
Short perc.
4.06
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.42
Range1M
0.48
Range3M
5.50
Volumes: Market Activity
Rel. volume
7.36
Price X volume
3.86M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.41 | 0.53 | Cheaper |
| Ent. to Revenue | 8.25 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 10.65 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 150.95 | 72.80 | Riskier |
| Debt to Equity | -9.55 | -1.23 | Cheaper |
| Debt to Assets | 0.57 | 0.25 | Expensive |
| Market Cap | 60.05M | 3.66B | Emerging |
